70290 Federal Register / Vol. 69, No. 232 / Friday, December 3, 2004 / Notices 

of the proposal review panel and the 

time, date, place, and any information 

on changes, corrections, or 

cancellations, please visit the NSF Website: http://www.nsf.gov/home/pubinfo/

advisory.htm. This information may also 

be requested by telephoning (703) 292–

8182.

Dated: November 29, 2004. 

Susanne Bolton, 

Committee Management Officer.

[FR Doc. 04–26582 Filed 12–2–04; 8:45 am] 

BILLING CODE 7555–01–M

NUCLEAR REGULATORY 

COMMISSION 

[Docket No. 030–33923] 

Notice of Availability of Environmental 

Assessment and Finding of No 

Significant Impact for License 

Termination for ViroPharma, 

Incorporated’s Facility in Exton, PA

AGENCY: Nuclear Regulatory 

Commission.

ACTION: Notice of availability.

FOR FURTHER INFORMATION CONTACT:

Marjorie McLaughlin, Decommissioning 

Branch, Division of Nuclear Materials 

Safety, Region I, 475 Allendale Road, 

King of Prussia, Pennsylvania 19406, 

telephone (610) 337–5240, fax (610) 

337–5269; or by e-mail: mmm3@nrc.gov.

SUPPLEMENTARY INFORMATION: 

I. Introduction 

The Nuclear Regulatory Commission 

(NRC) is terminating Materials License 

No. 37–30241–01 issued to ViroPharma, 

Incorporated and authorizing release of 

its facility in Exton, Pennsylvania for 

unrestricted use. NRC has prepared an 

Environmental Assessment (EA) in 

support of this action in accordance 

with the requirements of 10 CFR part 

51. Based on the EA, the NRC has 

concluded that a Finding of No 

Significant Impact (FONSI) is 

appropriate. The license will be 

terminated following the publication of 

this Notice. 

II. EA Summary 

The purpose of the action is to 

authorize the release of the licensee’s 

Exton, Pennsylvania facility for 

unrestricted use. ViroPharma, 

Incorporated was authorized by NRC 

from December 17, 1997, to use 

radioactive materials for research and 

development purposes at the site. On 

July 28, 2004, ViroPharma, Incorporated 

requested that NRC terminate the 

license and release the facility for 

unrestricted use. ViroPharma, 

Incorporated has conducted surveys of 

the facility and provided information to 

the NRC to demonstrate that the site 

meets the license termination criteria in 

subpart E of 10 CFR part 20 for 

unrestricted use. 

The NRC staff has prepared an EA in 

support of the license termination. The 

facility was remediated and surveyed 

prior to the licensee requesting the 

license amendment. The NRC staff has 

reviewed the information and final 

status survey submitted by ViroPharma, 

Incorporated. Based on its review, the 

staff has determined that there are no 

additional remediation activities 

necessary to complete the proposed 

action. Therefore, the staff considered 

the impact of the residual radioactivity 

at the facility and concluded that since 

the residual radioactivity meets the 

requirements in subpart E of 10 CFR 

part 20, a Finding of No Significant 

Impact is appropriate. 

III. Finding of No Significant Impact 

The staff has prepared the EA 

(summarized above) in support of the 

request to terminate the license and 

release the facility for unrestricted use. 

The NRC staff has evaluated 

ViroPharma, Incorporated’s request and 

the results of the surveys and has 

concluded that the completed action 

complies with the criteria in subpart E 

of 10 CFR part 20. The staff has found 

that the environmental impacts from the 

action are bounded by the impacts 

evaluated by NUREG–1496, Volumes 1–

3, ‘‘Generic Environmental Impact 

Statement in Support of Rulemaking on 

Radiological Criteria for License 

Termination of NRC–Licensed 

Facilities’’ (ML042310492, 

ML042320379, and ML042330385). On 

the basis of the EA, the NRC has 

concluded that the environmental 

impacts from the action are expected to 

be insignificant and has determined not 

to prepare an environmental impact 

statement for the action. 

IV. Further Information 

Documents related to this action, 

including the application for the license 

amendment and supporting 

documentation, are available 

electronically at the NRC’s Electronic 

Reading Room at http://www.nrc.gov/

reading-rm/adams.html. From this site, 

you can access the NRC’s Agencywide 

Document Access and Management 

System (ADAMS), which provides text 

and image files of NRC’s public 

documents. The ADAMS accession 

numbers for the documents related to 

this Notice are: The Environmental 

Assessment (ML043310216), and the 

letter dated July 28, 2004, requesting 

termination of the license 

(ML042230034). Please note that on 

October 25, 2004, the NRC terminated 

public access to ADAMS and initiated 

an additional security review of 

publicly available documents to ensure 

that potentially sensitive information is 

removed from the ADAMS database 

accessible through the NRC’s Web site. 

Interested members of the public may 

obtain copies of the referenced 

documents for review and/or copying by 

contacting the Public Document Room 

pending resumption of public access to 

ADAMS. The NRC Public Documents 

Room is located at NRC Headquarters in 

Rockville, MD, and can be contacted at 

(800) 397–4209, (301) 415–4737 or by email to: pdr@nrc.gov.

These documents may be viewed 

electronically at the NRC Public 

Document Room (PDR), 0 1 F21, One 

White Flint North, 11555 Rockville 

Pike, Rockville, MD 20852. The PDR 

reproduction contractor will copy 

documents for a fee. The PDR is open 

from 7:45 a.m. to 4:15 p.m., Monday 

through Friday, except on Federal 

holidays.

Dated at King of Prussia, Pennsylvania this 

26th day of November, 2004.

For the Nuclear Regulatory Commission. 

James P. Dwyer, 

Chief, Commercial and R&D Branch, Division 

of Nuclear Materials Safety, Region I.

[FR Doc. 04–26607 Filed 12–2–04; 8:45 am] 

BILLING CODE 7590–01–P

SECURITIES AND EXCHANGE 

COMMISSION 

Sunshine Act Meeting 

Notice is hereby given, pursuant to 

the provisions of the Government in the 

Sunshine Act, Pub. L. 94–409, that the 

Securities and Exchange Commission 

will hold the following meeting during 

the week of December 6, 2004: 

A Closed Meeting will be held on 

Thursday, December 9, 2004 at 2:30 

p.m. 

Commissioners, Counsel to the 

Commissioners, the Secretary to the 

Commission, and recording secretaries 

will attend the Closed Meeting. Certain 

staff members who have an interest in 

the matters may also be present. 

The General Counsel of the 

Commission, or his designee, has 

certified that, in his opinion, one or 

more of the exemptions set forth in 5 

U.S.C. 552b(c)(3), (5), (7), (9)(B), and 

(10) and 17 CFR 200.402(a)(3), (5), (7), 

9(ii) and (10), permit consideration of 

the scheduled matters at the Closed 

Meeting.